UTHR Stock Overview
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
UTHR passed our risk checks.
United Therapeutics Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$229.72 |
52 Week High | US$261.54 |
52 Week Low | US$204.44 |
Beta | 0.52 |
1 Month Change | 1.31% |
3 Month Change | 4.47% |
1 Year Change | 4.90% |
3 Year Change | 19.43% |
5 Year Change | 93.87% |
Change since IPO | 3,669.76% |
Recent News & Updates
United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Recent updates
United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17United Therapeutics reaches all-time high; shares up 15% YTD
Jul 06Why Hold United Therapeutics After Shares Doubled?
Jun 08With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting
May 06We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Apr 16Shareholder Returns
UTHR | US Biotechs | US Market | |
---|---|---|---|
7D | -3.0% | 0.9% | 0.2% |
1Y | 4.9% | 11.0% | 28.1% |
Return vs Industry: UTHR underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: UTHR underperformed the US Market which returned 28.8% over the past year.
Price Volatility
UTHR volatility | |
---|---|
UTHR Average Weekly Movement | 3.6% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: UTHR has not had significant price volatility in the past 3 months.
Volatility Over Time: UTHR's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 1,168 | Martine Rothblatt | https://www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
UTHR fundamental statistics | |
---|---|
Market cap | US$11.45b |
Earnings (TTM) | US$984.80m |
Revenue (TTM) | US$2.33b |
11.0x
P/E Ratio4.6x
P/S RatioIs UTHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UTHR income statement (TTM) | |
---|---|
Revenue | US$2.33b |
Cost of Revenue | US$257.50m |
Gross Profit | US$2.07b |
Other Expenses | US$1.09b |
Earnings | US$984.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 20.93 |
Gross Margin | 88.94% |
Net Profit Margin | 42.31% |
Debt/Equity Ratio | 11.7% |
How did UTHR perform over the long term?
See historical performance and comparison